On Thursday, drug manufacturer AbbVie Inc. (ABBV) announced two exclusive options and license agreements with Umoja Biopharma, a clinical-stage biotechnology company to develop multiple in-situ CAR-T cell therapy for patients with cancer.
Under the first agreement, AbbVie has the exclusive right to Umoja's CD19-directed in-situ generated CAR-T cell therapy candidate including UB-VV111, which is at an IND-enabling phase. Under the second agreement, both companies will develop up to four additional in-situ generated CAR-T cell therapy candidates for discovery targets.
The company said that with this collaboration it plans to develop next-generation in-situ CAR-T therapies.
Following the agreement, Umoja received upfront payments and a share in AbbVie. It is also eligible to receive up to $1.44 billion as option exercise fees and milestone payments, along with additional sales-based milestone payments and royalties.
Currently, AbbVie's stock is slipping 0.46%, to $160.29 on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.